Xiaobo Zhong

Xiaobo Zhong

Auto-generated profile, based on publicly available information

Xiaobo Zhong

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
NSNeil J Shah
Neil J Shah
VPVaibhav Patel
Vaibhav Patel
XZXiaobo Zhong
Xiaobo Zhong
LPLuis Pina
Luis Pina
JHJessica E Hawley
Jessica E Hawley
WOWilliam Oh
William Oh
TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood. We performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided. We identified 465 PCa patients (median age = 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] = 1.16, 95% confidence interval [CI] = 0.68 to 1.98, P = .59), hospitalization status (HR = 0.96, 95% CI = 0.52 to 1.77, P = .90), supplemental oxygenation (HR 1.14, 95% CI = 0.66 to 1.99, P = .64), and use of mechanical ventilation (HR = 0.81, 95% CI = 0.25 to 2.66, P = .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor–directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor–directed therapy: HR = 1.27, 95% CI = 0.69 to 2.32, P = .44). In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease.

12 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AWAn-Li Wang
An-Li Wang
XZXiaobo Zhong
Xiaobo Zhong
YHYasmin L. Hurd
Yasmin L. Hurd
Background: New York City is the US epicenter of the coronavirus disease 2019 (COVID-19) pandemic. Early international data indicated that comorbidity contributes significantly to poor prognosis and fatality in patients infected with SARS-CoV-2. It is not known to what degree medical comorbidity and sociodemographic determinants impact COVID-19 mortality in the US. Methods: Evaluation of de-identified electronic health records of 7,592 COVID-19 patients confirmed by SARS-CoV-2 lab tests in New York City. Medical comorbidites and outcome of mortality, and other covariates, including clinical, sociodemographic, and medication measures were assessed by bivariate and multivariate logistic regression models. Results: Of common comorbid conditions (hypertension, chronic kidney disease, chronic obstructive pulmonary disease, asthma, obesity, diabetes, HIV, cancer), when adjusted for covariates, chronic kidney disease remained significantly associated with increased odds of mortality. Patients who had more than one comorbidities, former smokers, treated with Azithromycin without Hydroxychloroquine, reside within the boroughs of Brooklyn and Queens Higher had higher odds of death. Conclusions: Increasing numbers of comorbid factors increase COVID-19 mortality, but several clinical and sociodemographic factors can mitigate risk. Continued evaluation of COVID-19 in large diverse populations is important to characterize individuals at risk and improve clinical outcomes.

1 October 2019 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
XZXiaobo Zhong
Xiaobo Zhong
BCBin Cheng
Bin Cheng
MQMin Qian
Min Qian
YCYing Kuen Cheung
Ying Kuen Cheung

6 October 2020 in Health Services Research
Verified
Journal Article
Closed access
PDF file
XZXiaobo Zhong
Xiaobo Zhong
JLJung‐Yi Lin
Jung‐Yi Lin
LLLihua Li
Lihua Li
ABAnna M. Barrett
Anna M. Barrett
JPJashvant Poeran
Jashvant Poeran
MMMadhu Mazumdar
Madhu Mazumdar

7 October 2019 in Journal of Health Care Chaplaincy
Verified
Journal Article
Closed access
XZXiaobo Zhong
Xiaobo Zhong
MMMadhu Mazumdar
Madhu Mazumdar
VSVansh Sharma
Vansh Sharma
LJLina Jandorf
Lina Jandorf
DWDenise Welsh
Denise Welsh
DMDeborah B. Marin
Deborah B. Marin
This study investigated patterns of spiritual care provided to inpatient infants and their parents, based on a taxonomy developed to describe spiritual care activities provided by chaplains. Data from 821 visits with 433 patients were included in the analyses. We applied a data-driven statistical approach, Latent Class Analysis (LCA), to identify patterns of taxonomy items that may be used for spiritual care. Three distinct patterns were identified and a predictive model was built to link a series of predictors to these patterns. Hospital length of stay and whether a visit is an initial or follow-up within an admission were significantly associated with the identified taxonomy patterns. These findings are helpful in understanding predictors and the nature of spiritual care delivery in an inpatient setting with infants. To our knowledge, this is the first application of LCA in research related to healthcare chaplaincy.

11 January 2021 in PeerJ
Verified
Journal Article
Open access
PDF file
XZXiaobo Zhong
Xiaobo Zhong
BCBin Cheng
Bin Cheng
XWXinru Wang
Xinru Wang
YCYing Kuen Cheung
Ying Kuen Cheung
This article introduces an R package, SMARTAR (Sequential Multiple Assignment Randomized Trial with Adaptive Randomization), by which clinical investigators can design and analyze a sequential multiple assignment randomized trial (SMART) for comparing adaptive treatment strategies. Adaptive treatment strategies are commonly used in clinical practice to personalize healthcare in chronic disorder management. SMART is an efficient clinical design for selecting the best adaptive treatment strategy from a family of candidates. Although some R packages can help in adaptive treatment strategies research, they mainly focus on secondary data analysis for observational studies, instead of clinical trials. SMARTAR is the first R package provides functions that can support clinical investigators and data analysts at every step of the statistical work pipeline in clinical trial practice. In this article, we demonstrate how to use this package, using a real data example.